At one year, the gemcitabine intravesical system, used to treat patients with Bacillus Calmette-Guerin-unresponsive, high-risk, papillary-only non-muscle invasive bladder cancer, showed high disease-free survival rate of 74%.

The Phase 2b trial also indicated over 95% of patients remained progression free and around 92% did not undergo bladder removal.

The investigational drug therapy was well-tolerated, with mild urinary side effects.

http://www.mtnewswires.com
Copyright © 2025 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.